Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2025-01-15 Investor Presentation
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Diasorin to present at J.P. Morgan Healthcare Conference 2025
Investor Presentation Classification · 99% confidence The document text explicitly states it is a 'presentation at 43rd Annual J.P. Morgan Healthcare Conference' and includes a date (January 15th, 2025) and location (San Francisco, CA). The content is structured as slides, featuring company strategy, product pipeline updates (LIAISON® MeMed BV®, Calprotectin 3.0, LymeDetect®, LIAISON PLEX®), and forward-looking statements typical of an investor presentation given at a major industry conference. This strongly aligns with the definition of an Investor Presentation (IP). Although it is presented at a conference, the core document is the presentation material itself, not the transcript (CT) or a general regulatory announcement (RNS).
2025-01-15 English
Diasorin S.p.A. - 2025 Annual Calendar of Corporate Events
Regulatory Filings Classification · 95% confidence The document is titled "Diasorin S.p.A. - 2025 Annual Calendar of Corporate Events" and lists scheduled dates for key corporate activities in 2025, including Board of Directors meetings for financial results approval, and the date for the Annual General Meeting (AGM). Since this document is an announcement detailing the schedule of future corporate events, including the AGM date, it functions as a forward-looking corporate calendar announcement. It is not the AGM presentation itself (AGM-R), nor is it a full financial report (10-K or IR). It is an announcement about corporate events, which fits best under the general category of Regulatory Filings (RNS) or potentially a specific announcement related to the AGM schedule. Given the options, and since it's a calendar of events rather than a specific report or transaction, RNS (Regulatory Filings) is the most appropriate general classification for this type of informational notice, although it heavily references AGM and financial reporting dates. However, since it explicitly mentions the date for the 'Annual General Meeting' and the approval of related items (like remuneration policy), it is closely tied to shareholder meetings. Since there isn't a specific 'Corporate Calendar' code, and it's a formal regulatory notice (Informazione Regolamentata), RNS is the safest fallback. If the document were only about the AGM, AGM-R might apply, but this covers the whole year's schedule.
2024-12-17 English
Diasorin S.p.A. - Calendario Annuale Eventi Societari 2025
Regulatory Filings Classification · 98% confidence The document is an official regulatory announcement (Informazione Regolamentata) from Diasorin S.p.A. dated December 17, 2024. The subject ('Oggetto') is 'Diasorin S.p.A. - Calendario Annuale Eventi Societari 2025' (Annual Calendar of Corporate Events 2025). It details future dates for Board of Directors meetings (approving financial results like the 2024 Annual Financial Statements and Q1/Q3 2025 results), the Annual General Meeting (AGM) date (April 28, 2025), and the expected dividend payment month. Since this document primarily announces the schedule of future corporate events, including the AGM and financial report releases, it is best classified as a general regulatory announcement that sets the stage for future filings. Given the content focuses on scheduling key corporate governance and financial reporting dates, it is not the report itself (like 10-K or IR), nor is it a specific announcement like a dividend declaration (DIV) or management change (MANG). It is a forward-looking schedule announcement. The closest fit among the provided options for a general schedule announcement that isn't a specific report or vote result is the general Regulatory Filings category (RNS), or potentially an AGM-R if the focus was solely on the AGM, but here it covers the entire year's financial calendar. However, since it explicitly lists the date for the AGM and the approval of the 2024 Financial Statements, it serves as a precursor to those events. Given the broad nature of scheduling corporate events, RNS (Regulatory Filings) is the most appropriate fallback for this type of administrative/scheduling notice that doesn't fit a more specific category like DIV or ER.
2024-12-17 Italian
Diasorin S.p.A. - Allegato 3F
Transaction in Own Shares Classification · 99% confidence The document is a formal disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Model Disclosure for Transactions in the Issuer's Securities) concerning Diasorin S.p.A. Section 2 details specific transactions involving the company's shares (Azioni) during November 2024, including dates, quantities, and prices. The annotations explicitly state these are sales of treasury shares following the exercise of stock options. This structure perfectly matches the definition of reporting personal share transactions by executives or, in this case, transactions related to employee share schemes, which falls under Director's Dealing (DIRS) or Transaction in Own Shares (POS). Since the document details the company selling its own shares (treasury shares) related to option plans, 'Transaction in Own Shares' (POS) is the most precise fit, as it covers the company's activity regarding its own stock repurchase/issuance, which is what happens when options are exercised and shares are sold from treasury stock to employees. However, the context of insider/executive transactions is often grouped with DIRS. Given the explicit focus on the company executing sales of its own shares ('operazioni di vendita di azioni proprie'), POS is the primary classification. If POS were not available, DIRS might be considered, but POS is more specific to the action described (Transaction in Own Shares).
2024-12-09 Italian
Communication on total amount of voting rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS' and details changes in the number of voting rights held by shareholders, specifically mentioning the assignment and waiver of 'increased voting rights' based on Consob Regulation. This type of announcement, which reports on the structure of voting rights and share capital, aligns closely with regulatory disclosures concerning ownership structure and shareholder rights. While it is a specific regulatory communication, it does not fit perfectly into the standard categories like 10-K, ER, or IR. It is a formal regulatory update regarding share structure and voting power. The closest fit among the provided options that deals with ownership structure changes or formal regulatory disclosures about share capital/voting rights is not explicitly listed, but the content is highly specific to shareholder voting rights structure. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most relevant category, as the document explicitly communicates the total amount of voting rights after adjustments. It is not a general regulatory filing (RNS) because it is highly specific to voting rights mechanics.
2024-11-07 English
Comunicazione dell'ammontare complessivo dei diritti di voto
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'COMUNICAZIONE DELL'AMMONTARE COMPLESSIVO DEI DIRITTI DI VOTO' (Communication of the Total Amount of Voting Rights) and explicitly references Article 85-bis, paragraph 4-bis, of the Consob Regulation n. 11971/1999. It details changes in the number of voting rights due to the accrual or waiver of the 'maggiorazione del diritto di voto' (voting right premium). This specific disclosure relates directly to the structure of shareholder voting rights following general meeting mechanics or related corporate actions, which falls under the scope of voting results or related governance announcements. While it is not the final result of a vote (DVA), it is a formal announcement concerning voting rights structure. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit as it covers announcements related to voting rights, even if it's an update on the voting rights structure rather than the final tally of a specific resolution.
2024-11-07 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.